Radioimmunotherapy with alpha-emitting nuclides

European Journal of Nuclear Medicine

Volumn 25, Issue 9, 1998, Pages 1341-1351

  McDevitt, Michael R ^a   Sgouros, George ^a   Finn, Ronald D ^a   Humm, John L ^a   Jurcic, Joseph G ^a   Larson, Steven M ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Actinium 225; Alpha particle emitting radionuclides; Astatine 211; Bismuth 212; Bismuth 213; High linear energy transfer

Indexed keywords

ACTINIUM; ASTATINE 211; BISMUTH; CHELATING AGENT; FERMIUM; IMMUNOGLOBULIN G; LEAD 212; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM; TERBIUM;

ALPHA RADIATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CLINICAL RESEARCH; CYTOTOXICITY; DOSIMETRY; DRUG DISTRIBUTION; DRUG MANUFACTURE; DRUG TARGETING; HALF LIFE TIME; HUMAN; LINEAR ENERGY TRANSFER; METHODOLOGY; NONHUMAN; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; REVIEW; STATISTICS; TUMOR CELL;

ALPHA PARTICLES; ANIMALS; HUMANS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE;

EID: 0031715792     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050306     Document Type: Review

References (68)

1. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol 1996; 41: 1905-1914.
2. Vaidyanathan G, Zalutsky MR. Targeted therapy using alpha emitters. Phys Med Biol 1996; 41: 1915-1931.
3. Zalutsky MR, Schuster JM, Garg PK, Archer GE Jr, Dewhirst MW, Bigner DD. Two approaches for enhancing radioimmunotherapy: α-emitters and hyperthermia. Recent Results Cancer Res 1996; 141: 101-112.
4. Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha particle-emitting radioimmunoconjugates. Acta Oncol 1996; 35: 373-379.
5. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1987; 13: 1767-1773.
6. Kocher DC. Radioactive decay data tables: a handbook of decay data for application to radiation dosimetry and radiological assessments. Springfield, VA: US Department of Energy/Technical Information Center; 1981: 61-67.
7. Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunoconj Radiopharm 1991; 4: 85-97.
8. 2 fragments with the alpha particle emitting nuclide astatine-211: preservation of immunoreactivity with in vivo localizing capacity. Proc Natl Acad Sci USA 1989; 86: 7149-7153.
9. Atcher RN, Friedman AM, Hines JJ. An improved generator for the production of Bi-212 and Bi-212 from Ra-224. Appl Radiat Isot 1988; 39: 283-286.
10. Atcher RW, Hines JJ, Friedman AM. A remote system for the separation of Th-228 and Ra-224. J Radioanal Nucl Chem 1987; 117(3): 155-162.
11. Brechbiel MW, Pippin CG, McMurry TJ, Milenic D, Roselli M, Colcher D, Gansow OA. An effective chelating agent for labeling of monoclonal antibody with Bi-212 for α-particle mediated radioimmunotherapy. J Chem Soc Chem Commun 1991; 1169-1170.
12. Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepentaacetic acids for labeling of monoclonal antibodies with the bismuth-212 α-particle emitter. J Chem Soc Perkin Trans 1992; 1: 1173-1178.
13. Mausner LF, Straub RE, Srivastava SC. The "in vivo" generator for radioimmunotherapy. J Lab Comp Radiopharm 1989; 26: 177-178.
14. Kumar K, Magerstadt M, Gansow OA. Lead(II) and bismuth(III) complexes of the polyazacyclo-alkane-N-acetic acids nota, dota, and teta. J Chem Soc Chem Commun 1989: 145-146.
15. Gansow OA, Brechbiel MW, Pippin CG, McMurry TJ, Lambrecht R, Colcher D, Schlom J, Roselli M, Strand M, Huneke RB, Ruegg CL. Lead and bismuth complexes of functionalized DTPA ligands and of the the polyazacycloalkane-N-acetic acids dota. Utility for radioimmunoimaging and radioimmunotherapy. Antibody Immunoconj Radiopharm 1991; 4: 413-425.
16. 213Bi for alpha-particle-mediated radioimmunotherapy. J Lab Comp Radiopharm 1997; XL: 341.
17. Van Geel JNC, Fuger J, Koch L. Verfahren zur Erzeugung von Actinium-225 und Wismuth-213. European Patent nb. 0 443 479 B1, 1994.
18. Methods for the production of Ac-225 and Bi-225 for alpha immunotherapy. ITU Annual Report 1995 - (EUR 16368) - Basic Actinide Research 1995: 55-56.
19. Geerlings MW Sr, Kaspersen FM, Apostolidis C, Van Der Hout R. The feasibility of Ac-225 as a source of α-particles in radioimmunotherapy. Nucl Med Commun 1993; 14: 121-125.
20. Kaspersen FM, Bos E, Doornmalen AV, Geerlings MW Sr, Apostolidis C, Molinet R. Cytotoxicity of Bi-213 and Ac-225 immunoconjugates. Nucl Med Commun 1995; 16: 468-476.
21. McDevitt MR, Nikula TN, Finn RD, Curcio MJ, Gansow OA, Geerlings MW Sr, Larson SM, Scheinberg DA. Bismuth labeled antibodies for therapy of leukemias, lymphomas, and carcinomas: preclinical studies. Tumor Targeting 1996; 2: 182.
22. Spivakov BY, Stoyanov ES, Gribov LA, Zolotov YA. Raman laser spectroscopic studies of bismuth(III) halide complexes in aqueous solutions. J Inorg Nucl Chem 1979; 41: 453-155.
23. Nikula TN, Curcio MJ, Brechbiel MW, Gansow OA, Kinn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 1995; 22: 387-390.
24. Finn RD, McDevitt MR, Scheinberg DA, Jurcic JG, Larson SM, Sgouros G, Humm JL, Curcio MJ, Brechbiel MW, Gansow OA, Geerlings MW Sr, Apostolidas C, Molinet R. Refinements and improvements for Bi-213 production and use as a targeted therapeutic radiopharmaceutical. J Lab Comp Radiopharm 1997; XL: 293.
25. Jurcic JG, McDevitt MR, Sgouros G, Ballangrud A, Finn RD, Geerlings MW Sr, Humm JL, Molinet R, Apostolidis C, Larson SM, Scheinberg DA. Targeted alpha particle therapy for myeloid leukemias: a phase I trial of Bismuth-213-HuM195 (anti-CD33). Blood 1997; 90 (Suppl): 504a.
26. Sgouros G, Humm JL, McDevilt MR, Kennedy J, Schumaker R, Larson SM, Scheinberg DA. Bismuth-213 imaging: preclinical characterization of an alpha-particle emitting radionuclide. J Nucl Med 1996; 37: 78P.
27. Sgouros G, Erdi YL, Humm JL, Mehta B, McDevitt MR, Finn RD, Jurcic JG, Larson SM, Scheinberg DA. Pharmacokinetics and dosimetry of an alpha particle emitter labeled anti-CD33 antibody ([Bi-213]HuM195) in patients with leukemia. J Nucl Med 1997; 38: 231P.
28. Ballangrud AM, Humm JL, McDevitt MR, Finn RD, Jurcic JG, Larson SM, Scheinberg DA, Sgouros G. Normal organ dosimetry of leukemia patients treated with HuM195 labeled with the alpha particle emitter bismuth-213. To be presented to the Society of Nuclear Medicine 45th Annual Meeting, Toronto; June 7-11, 1998.
29. Gangwer TE, Goldstein M, Pillay KKS. Radiation effects on ion exchange materials. BNL 50781, November 1977, p 60.
30. Weber DA, Eckerman KF, Dillman LT, Ryman JC. MIRD: radionuclide data and decay schemes. The Society of Nuclear Medicine, Inc. 1989.
31. Wu C, Brechhiel MW, Gansow OA. An improved generator lor the production of Bi-213 from Ac-225. Abstracts of Papers of the American Chemical Society 1996; 212: 61-NUCL.
32. Mirzadeh S, Kennel SJ. Optimizations of radiolabeling of immunoproteins with Bi-213. Abstracts of Papers of the American Chemical Society 1996; 212: 62-NUCL.
33. Bigler RE, Zanonico PB, Cosma M, Sgouros G. Adjuvant radioimmunotherapy for micrometastasis: a stategy for cancer therapy. Proc NATO Adv Study Inst, Radiolabeled monoclonal antibodies for imaging and therapy: potential, problems, and prospects. II Ciocco, Italy, July 1986.
34. Atcher RW, Friedman AM, Huizenga JR, Spencer, RP. A radionuclide generator tor the production of Pb-211 and its daughters. J Radioanal Nucl Chem 1989; 135: 215-221.
35. Allen BJ, Blagojevic N, Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149. Nucl Med Commun 1996; 17: 40-47.
36. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversais of the cell nucleus. Radiat Res 1991; 128: 204-209.
37. Kozak, RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA 1986; 83: 474-478.
38. Kurtzman SH, Russo A, Mitchell JB, DeGraff W, Sindelar WF, Brechbiel MW, Gansow OA, Friedman AM, Hines JJ, Gamson J, Atcher RW. Bismuth-212 linked to an antipancreatic carcinoma antibody: model for alpha-particle emitter radioimmunotherapy. J Natl Cancer Inst 1988; 80: 449-452.
39. Macklis RM, Kinsey BM, Kassis AL, Ferrara JLM, Atcher RW, Hines JJ, Coleman CN, Adelstein SJ, Burackoff SJ. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 1988; 240: 1024-1026.
40. Harrison A, Royle L, Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma. NCI Monogr 1987; 3: 157-158.
41. Zalutsky MR, McLendon RH, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res 1994; 54: 4719-4725.
42. Beyer GJ, Offord R, Kunzi G, Aleksandrova Y, Ravn U, Jahn S, Barker J, Tengblad O, Lindroos M. The influence of EDT-MP-concentration on the biodistribution of radiolanthanides and Ac-225 in tumor-bearing mice. The ISOLDE Collaboration. Nucl Med Biol 1997; 24: 367-372.
43. Howell RW, Goddu SM, Narra VR, Fisher DR, Schemer RH, Rao DV. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha particle emitters in vivo. Radiat Res 1997; 147: 342-348.
44. Fisher DR, Sgouros G, Dosimetry of radium-223 and progeny. Proceedings of the 6th International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, Tenn., May 7-10, 1996.
45. Humphreys ER, Humm JL. A Monte-Curio approach to the microdosimetry of Ra-224 in imirine compact and cancellous bone. Health Phys 1988; 54: 607-615.
46. Humm JL, Chin LM. A model of cell inactivation by alpha particle internal emitters. Radiat Res 1993; 134: 143-150.
47. Fisher DR, Harty R. The microdosimetry of lymphocytes irradiated by alpha-particles. Int J Radiat Biol 1982; 41: 315-324.
48. Stinchcomb TG, Roeske JC. Analytic microdosimetry for radioimmunotherapeutic alpha emitters. Med Phys 1992; 19: 1385-1393.
49. Humm JL, Roeske JC, Fisher DR, Chen GTY. Microdosimetric concepts in radioimmunotherapy. Med Phys 1993; 20: 535-543.
50. Humm JL, Mackliss RM, Bump K, Cobb LM, Chin LM. Internal dosimetry using data derived from tissue autoradio-graphs. J Nucl Med 1993; 34: 1811-1817.
51. Roeske JC, Stinchcomb TG. Dosimetric framework for therapeutic alpha-particle emitters. J Nucl Med 1997; 38: 1923-1929.
52. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: adsorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994; 35: 303-316.
53. Loevinger R, Budinger TF, Watson, EE. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine, 1989.
54. Macklis RM, Yin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: induction of apoptosis. Radiat Res 1992: 130: 220-226.
55. Simonson RB, Ultee ME, Hauler JA, Alvarez VL. Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified Bi-212-labeled antibody. Cancer Res 1990; 50: 985s-988s.
56. Scheinberg DA, Strand M. Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer Rex 1982; 42: 44-49.
57. Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelate conjugated monoclonal antibodies. Science 1982; 215: 1511-1513.
58. Scheinberg DA, Strand M. Kinetic and catabolic considerations of monoclonal antibody targeting in erythro-leukemic mice. Cancer Res 1983; 43: 265-272.
59. Reugg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990; 50: 4221-4226.
60. Huneke RB, Pippin CG, Squire RA, Brechbiel MW. Gansow OA, Strand M. Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res 1992; 52: 5818-5820.
61. Junghans RP, Dobbs D, Brechbiel MW, Mirzadeh S, Raubitschek AA, Gansow OA, Waldmann TA. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane N,N′,N″,N‴-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for α-emitter (Bi-212) therapy. Cancer Res 1993; 53: 5683-5689.
62. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res 1994; 54: 4719-4725.
63. Link EM, Carpenter RN. At-211-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases. Cancer Res 1990; 50: 2963-2967.
64. Link EM, Blower PJ, Costa DC, Ell PJ, Spittle MF. At-211-methylene blue treatment of disseminated melanoma. Melanoma Res 1997: 7 Suppl 1: s44.
65. Caron PC, Co MS, Bull MK. Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52: 6761-6767.
66. Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 1989; 3: 440-445.
67. Nikula TK, Finn RD, Gansow OA, Kozak R, Pippin CG, Wu C, Geerlings MW Sr, Apostolidis C, Curcio MJ, Scheinberg DA. Alpha particle-emitting constructs of recombinant humanized anti-CD33 for myeloid leukemia. J Immunother 1994; 16: 149.
68. Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, Miller WH Jr, Geerlings MW Sr, Warrell RP Jr, Larson SM, Scheinberg DA. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995; 55 (23 Suppl): 5908s-5910s.